Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

Yi-Sheng Chang, WAN-JU Annabelle Lee, Chen Chee Lim, Shih Hao Wang, Sheng-Min Hsu, Yi Chian Chen, Chia Yi Cheng, Yu Ti Teng, Yi-Hsun Huang, Chun-Chieh Lai, Sung Huei Tseng

Research output: Contribution to journalArticle

Abstract

This study investigated the "real-world" use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012-2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.

Original languageEnglish
Article number7486
JournalScientific reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Macular Degeneration
Taiwan
National Health Programs
Visual Acuity
Epiretinal Membrane
Ranibizumab
Cicatrix
Medical Records
Injections
Therapeutics

All Science Journal Classification (ASJC) codes

  • General

Cite this

Chang, Yi-Sheng ; Lee, WAN-JU Annabelle ; Lim, Chen Chee ; Wang, Shih Hao ; Hsu, Sheng-Min ; Chen, Yi Chian ; Cheng, Chia Yi ; Teng, Yu Ti ; Huang, Yi-Hsun ; Lai, Chun-Chieh ; Tseng, Sung Huei. / Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{9f1223002a0042389d2d52c0e3c94816,
title = "Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan",
abstract = "This study investigated the {"}real-world{"} use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012-2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5{\%}) in 179 patients (65.5{\%} men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8{\%} of eyes and stabilising in 38.3{\%} of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.",
author = "Yi-Sheng Chang and Lee, {WAN-JU Annabelle} and Lim, {Chen Chee} and Wang, {Shih Hao} and Sheng-Min Hsu and Chen, {Yi Chian} and Cheng, {Chia Yi} and Teng, {Yu Ti} and Yi-Hsun Huang and Chun-Chieh Lai and Tseng, {Sung Huei}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-25864-0",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan. / Chang, Yi-Sheng; Lee, WAN-JU Annabelle; Lim, Chen Chee; Wang, Shih Hao; Hsu, Sheng-Min; Chen, Yi Chian; Cheng, Chia Yi; Teng, Yu Ti; Huang, Yi-Hsun; Lai, Chun-Chieh; Tseng, Sung Huei.

In: Scientific reports, Vol. 8, No. 1, 7486, 01.12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

AU - Chang, Yi-Sheng

AU - Lee, WAN-JU Annabelle

AU - Lim, Chen Chee

AU - Wang, Shih Hao

AU - Hsu, Sheng-Min

AU - Chen, Yi Chian

AU - Cheng, Chia Yi

AU - Teng, Yu Ti

AU - Huang, Yi-Hsun

AU - Lai, Chun-Chieh

AU - Tseng, Sung Huei

PY - 2018/12/1

Y1 - 2018/12/1

N2 - This study investigated the "real-world" use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012-2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.

AB - This study investigated the "real-world" use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012-2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.

UR - http://www.scopus.com/inward/record.url?scp=85046947769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046947769&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-25864-0

DO - 10.1038/s41598-018-25864-0

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 7486

ER -